Deals

United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug

Gene Therapy, Results

Bolstered by promising PhIIb snapshot, uniQure plays catch-up with Spark in the race to a hemophilia B gene therapy

Collaborations, Immuno-oncology, Research Institutes

The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells
More news caret

calendar Protocols

Quick hits from around the biopharma web

Nov 15

Centrexion delays IPO; Exelixis makes $40M as Cabometyx wins EU nod

Nov 14

Pfizer loses key Lyrica patent battle in the UK; Kleo Pharma closes $21M Series B round

Nov 13

Roche wins speedy FDA review for Tecentriq; South Korean authorities to look into Samsung BioLogics accounting practices

Nov 12

OrbiMed leads $70M raise for Harpoon Therapeutics; Ziopharm inks combo deal with Regeneron's PD-1

More Protocols caret

person Peer Review

Weekly biopharma careers news report

Nov 9

One year in, Joanne Kotz assumes CEO role at Jnana; President/Executive chair duo will now run BlackThorn

Nov 2

Sun BioPharma founder Michael Cullen steps up; SemaThera settles on permanent CEO; OncoSec nabs Kellie Malloy Foerter from Syneos

Oct 26

Longtime Apitope CEO Keith Martin steps down; Clearside Biomedical taps Spark exec as CMO

Oct 19

Medivir taps ex-Acadia chief Uli Hacksell as interim CEO; Merck onboards chief digital officer

More peer review caret

Dollar Premium

Winners and losers at #ESMO18

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

Global reach: The top 25 biopharma companies in the world

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

bullhorn Bioregnum

The view from John Carroll

Nov 7

Bound to the hip with Trump, ex-Celgene chief Bob Hugin gets whipped in New Jersey Senate race

Oct 25

Fight! Trump kicks off a war of words with the drug lobby, proposing to peg Medicare prices to overseas rates

Oct 3

Sarepta shares yo-yo in the red on another glimpse of stellar results for Duchenne MD gene therapy — what gives?

Sep 13

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

More opinion caret

twitter Marco

Hot BioTwitter bot - last updated ago

arrow-thick Most Viral

Nebula Genomics, with free DNA sequencing, opens for business - STAT

STAT a day

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline

ENDPOINTS NEWS Endpoints Staff a day

Xconomy: Data Starts Stretch Run for UniQure's Upgraded Hemophilia Gene Therapy

Xconomy Ben Fidler a day

United Therapeutics pays $800M-plus to grab Arena's PhIII PAH drug

ENDPOINTS NEWS Endpoints Staff a day

Scientists hope to translate paralyzed patients' thoughts into speech - STAT

STAT a day

PMA Denials: Why so Few?

RAPS a day

Nvidia Earnings Live Blog

TheStreet Eric Jhonsa a day

United Therapeutics licenses Arena hypertension drug for up to $1.2B

STAT a day

Xconomy: Arena's Comeback Continues with $800M Deal for Blood Disease Drug

Xconomy Frank Vinluan a day

The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells

ENDPOINTS NEWS John Carroll a day

timer Latest

Science | AAAS

Dietary fat: From foe to friend?

TheStreet

Nvidia Earnings Live Blog

Evaluate.com

Novel drug approvals set to hit a new record in 2018

Regulations

Comments from Novartis Services, Inc. on Pfizer, Inc.'s Citizen Petition.

ENDPOINTS NEWS

The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells

RAPS

PMA Denials: Why so Few?

NPR.org

There's Growing Fear The Ebola Outbreak In Congo Could Get Much Worse

JAMA

Accuracy of a Deep Learning Algorithm for Detection of Diabetic Retinopathy

STAT

A big Indian generics maker failed an FDA inspection, but how bad was it? - STAT

STAT

United Therapeutics licenses Arena hypertension drug for up to $1.2B

fire Hot This Week

1

Forbes

30 Under 30 2019: Healthcare

2

Forbes

Amarin's Fish Oil Derived Drug Shows Great Promise - With Big Caveats

3

STAT

Sean Parker: Health care breakthroughs aren't going to come from Google, Amazon

4

Mrknewsroom

Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration

5

STAT

Nebula Genomics, with free DNA sequencing, opens for business - STAT

6

STAT

Amarin, Vascepa, and mineral oil. There's more to consider with this fish-oil story

7

Forbes

At 24, Two Entrepreneurs Took On Cancer. At 32, They're Worth Hundreds Of Millions

8

Biotech Strategy Blog

How the microbiota impact response to cancer immunotherapy | Biotech Strategy Blog

9

ENDPOINTS NEWS

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline

10

Xconomy

Xconomy: Kymera Adds $65M in New Funding and Eyes First Clinical Test

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back